JP5775245B2 - 免疫不全障害の治療のために免疫調節化合物を用いる方法及び組成物 - Google Patents

免疫不全障害の治療のために免疫調節化合物を用いる方法及び組成物 Download PDF

Info

Publication number
JP5775245B2
JP5775245B2 JP2007544475A JP2007544475A JP5775245B2 JP 5775245 B2 JP5775245 B2 JP 5775245B2 JP 2007544475 A JP2007544475 A JP 2007544475A JP 2007544475 A JP2007544475 A JP 2007544475A JP 5775245 B2 JP5775245 B2 JP 5775245B2
Authority
JP
Japan
Prior art keywords
compounds
alkyl
cells
carbon atoms
dioxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007544475A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008521916A (ja
JP2008521916A5 (https=
Inventor
ク ウェイミング
ク ウェイミング
ジー． コルラル ラウラ
ジー． コルラル ラウラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2008521916A publication Critical patent/JP2008521916A/ja
Publication of JP2008521916A5 publication Critical patent/JP2008521916A5/ja
Application granted granted Critical
Publication of JP5775245B2 publication Critical patent/JP5775245B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007544475A 2004-12-01 2005-11-30 免疫不全障害の治療のために免疫調節化合物を用いる方法及び組成物 Expired - Fee Related JP5775245B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63187004P 2004-12-01 2004-12-01
US60/631,870 2004-12-01
PCT/US2005/043360 WO2006060507A2 (en) 2004-12-01 2005-11-30 Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012176776A Division JP2012255009A (ja) 2004-12-01 2012-08-09 免疫不全障害の治療のために免疫調節化合物を用いる方法及び組成物

Publications (3)

Publication Number Publication Date
JP2008521916A JP2008521916A (ja) 2008-06-26
JP2008521916A5 JP2008521916A5 (https=) 2009-01-22
JP5775245B2 true JP5775245B2 (ja) 2015-09-09

Family

ID=36143704

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007544475A Expired - Fee Related JP5775245B2 (ja) 2004-12-01 2005-11-30 免疫不全障害の治療のために免疫調節化合物を用いる方法及び組成物
JP2012176776A Pending JP2012255009A (ja) 2004-12-01 2012-08-09 免疫不全障害の治療のために免疫調節化合物を用いる方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012176776A Pending JP2012255009A (ja) 2004-12-01 2012-08-09 免疫不全障害の治療のために免疫調節化合物を用いる方法及び組成物

Country Status (13)

Country Link
US (1) US8394832B2 (https=)
EP (1) EP1924250B1 (https=)
JP (2) JP5775245B2 (https=)
KR (1) KR20070090227A (https=)
CN (1) CN101111234A (https=)
AU (1) AU2005311888A1 (https=)
BR (1) BRPI0518793A2 (https=)
CA (1) CA2588990A1 (https=)
IL (1) IL183537A0 (https=)
MX (1) MX2007006439A (https=)
NZ (1) NZ555886A (https=)
WO (1) WO2006060507A2 (https=)
ZA (1) ZA200704964B (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009010082A (es) 2007-03-20 2009-10-19 Celgene Corp Derivados y composiciones que comprenden isoindolina 4'-o-sustituida y metodos para utilizar la misma.
CA2704710C (en) 2007-09-26 2016-02-02 Celgene Corporation 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising the same
WO2009085234A2 (en) 2007-12-20 2009-07-09 Signal Pharmaceuticals, Inc. Use of micro-rna as a biomarker of immunomodulatory drug activity
WO2009105256A2 (en) * 2008-02-20 2009-08-27 Celgene Corporation Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
US20090298882A1 (en) * 2008-05-13 2009-12-03 Muller George W Thioxoisoindoline compounds and compositions comprising and methods of using the same
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
PT2358697E (pt) 2008-10-29 2016-02-03 Celgene Corp Compostos de isoindolina para utilização no tratamento do cancro
US20120053159A1 (en) 2009-02-11 2012-03-01 Muller George W Isotopologues of lenalidomide
EP3489352A1 (en) 2009-03-25 2019-05-29 Celularity, Inc. Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
CN103800906B (zh) 2009-03-25 2017-09-22 德克萨斯大学系统董事会 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物
EP2436387B1 (en) 2009-05-25 2018-07-25 Celgene Corporation Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex
CN101696205B (zh) 2009-11-02 2011-10-19 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
BR112012015129A2 (pt) 2009-12-22 2019-09-24 Celgene Corp "composto, composição farmacêutica e método para tratar, controlar ou prevenir uma doença ou distúrbio"
MX337566B (es) 2010-01-05 2016-03-10 Celgene Corp Combinación de un compuesto inmunomodulador y una artemisinina o un derivado de ésta para tratar cáncer.
PL3202460T3 (pl) 2010-02-11 2019-12-31 Celgene Corporation Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
EP2663549B1 (en) 2011-01-10 2018-03-14 Celgene Corporation Phenethylsulfone isoindoline derivatives as inhibitors of pde 4 and/or cytokines
DK2683708T3 (da) 2011-03-11 2018-01-29 Celgene Corp Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf
EP2699091B1 (en) 2011-03-28 2017-06-21 DeuteRx, LLC 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
WO2012145309A1 (en) 2011-04-18 2012-10-26 Celgene Corporation Biomarkers for the treatment of multiple myeloma
AU2012249491B2 (en) 2011-04-29 2016-12-15 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
US20140221427A1 (en) 2011-06-22 2014-08-07 Celgene Corporation Isotopologues of pomalidomide
RS60415B1 (sr) 2011-12-27 2020-07-31 Amgen (Europe) GmbH Formulacije (+)-2-[1-(3-etoksi-4-metoksi-fenil)-2-metansulfonil-etil]-4-acetil aminoizoindolin-1,3-diona
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
US9249093B2 (en) 2012-04-20 2016-02-02 Concert Pharmaceuticals, Inc. Deuterated rigosertib
ES2872967T3 (es) 2012-06-29 2021-11-03 Celgene Corp Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
EP2922838B1 (en) 2012-10-22 2018-03-14 Concert Pharmaceuticals Inc. Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione} .
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
JP6359563B2 (ja) 2013-01-14 2018-07-18 デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ， ＬＬＣ ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体
BR112015025252A2 (pt) 2013-04-02 2017-07-18 Celgene Corp métodos e composições usando 4-amino-2-(2,6-dioxo-piperidina-3-il)-isoindolina-1,3-diona para tratamento e gestão de cânceres de sistema nervoso central
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
EP3827836A1 (en) 2014-06-27 2021-06-02 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
WO2017117118A1 (en) 2015-12-28 2017-07-06 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
BR112020017053A2 (pt) 2018-02-21 2020-12-15 Celgene Corporation Anticorpos que se ligam ao bcma e usos dos mesmos
BR122022012697B1 (pt) 2018-07-10 2023-04-04 Novartis Ag Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US20030013649A1 (en) * 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
US7521463B2 (en) * 2000-07-31 2009-04-21 University Of Maryland, Baltimore Immunomodulatory compounds
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
JP2004083564A (ja) * 2002-05-31 2004-03-18 Takeda Chem Ind Ltd 新規スクリーニング方法
US7119713B2 (en) 2002-06-27 2006-10-10 Elster Electricity, Llc Dynamic self-configuring metering network
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CA2560221C (en) * 2004-03-22 2010-12-07 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
MX2009010082A (es) * 2007-03-20 2009-10-19 Celgene Corp Derivados y composiciones que comprenden isoindolina 4'-o-sustituida y metodos para utilizar la misma.

Also Published As

Publication number Publication date
US20060188475A1 (en) 2006-08-24
JP2012255009A (ja) 2012-12-27
WO2006060507A2 (en) 2006-06-08
JP2008521916A (ja) 2008-06-26
KR20070090227A (ko) 2007-09-05
EP1924250B1 (en) 2017-01-04
AU2005311888A1 (en) 2006-06-08
ZA200704964B (en) 2008-10-29
IL183537A0 (en) 2007-09-20
NZ555886A (en) 2009-12-24
AU2005311888A2 (en) 2008-07-17
WO2006060507A3 (en) 2006-08-03
WO2006060507A9 (en) 2007-06-28
US8394832B2 (en) 2013-03-12
CN101111234A (zh) 2008-01-23
MX2007006439A (es) 2007-07-20
CA2588990A1 (en) 2006-06-08
EP1924250A2 (en) 2008-05-28
BRPI0518793A2 (pt) 2008-12-09

Similar Documents

Publication Publication Date Title
JP5775245B2 (ja) 免疫不全障害の治療のために免疫調節化合物を用いる方法及び組成物
AU2011202457B2 (en) Methods and compositions for the treatment and management of hemoglobinopathy and anemia
JP4481828B2 (ja) 骨髄異形成症候群を治療および管理するための免疫調節化合物の使用方法およびそれを含む組成物
US20060154880A1 (en) Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
PT1505973E (pt) Combinações para o tratamento de mieloma múltiplo
CA2621136A1 (en) Immunological uses of immunodulatory compounds for vaccine and anti-infectious disease therapy
KR20070010184A (ko) 폐 고혈압증의 치료 및 관리를 위한 면역조절 화합물의사용 방법 및 상기 화합물을 포함하는 조성물
JP2006510606A (ja) 骨髄異形成症候群を治療および管理するための選択的サイトカイン阻害剤の使用方法およびそれを含む組成物
JP2010506937A (ja) スピロヘータ及びその他の偏性細胞内細菌性疾患の治療及び管理のために免疫調節化合物を用いる方法及び組成物
CN101495111A (zh) 在联合治疗中使用免疫调节化合物的方法和组合物
JP2009507836A (ja) 低血漿レプチンレベルに関連した障害治療のために、免疫調節性化合物を用いる方法、及びそれを用いた組成物
EP1744748A2 (en) Method of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myelodysplastic syndromes
JP2011503062A (ja) 内皮機能障害に伴う障害の治療のための免疫調節化合物の使用
HK1112415A (en) Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
MXPA06011793A (es) Uso de farmacos inhibidores selectivos de citocina en los sindromes mieldisplasticos.
KR20070011491A (ko) 골수이형성 증후군에서의 선택적 사이토킨 억제 약물의용도
HK1111898A (en) Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111104

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120809

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120824

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20120914

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140213

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141212

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150123

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150703

R150 Certificate of patent or registration of utility model

Ref document number: 5775245

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees